Zepbound vs Mounjaro isn't a choice between two drugs. Both are tirzepatide from Eli Lilly, in the same strengths. The FDA label is the difference: Zepbound is for weight management and for sleep apnea with obesity; Mounjaro is for type 2 diabetes. That label drives what insurance covers and what you pay.
The price table below shows what each costs with and without insurance, checked October 27, 2026.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
Decision Verdict
If you have type 2 diabetes, Mounjaro is the tirzepatide brand labeled for it; if you don't, Zepbound is the brand labeled for weight and sleep apnea, and with on-time refills it's the cheaper one to buy yourself.
- Best for: Zepbound suits adults with obesity, or with overweight plus a weight-related condition, adults with obesity and moderate to severe obstructive sleep apnea, anyone paying cash, and Medicare Part D members who qualify for the Medicare GLP-1 Bridge. Mounjaro suits adults and children 10 and older with type 2 diabetes, including adults with type 2 diabetes at high risk of heart attack or stroke.
- Not ideal for: Either brand, if you or a family member has had medullary thyroid carcinoma or MEN 2; both labels carry the same boxed warning for thyroid C-cell tumors. Mounjaro is a poor fit if you don't have type 2 diabetes: weight loss isn't on its label, and Lilly's Mounjaro savings card requires an approved use.
- The factor that matters most: Your diagnosis and your plan's drug list. No web page can tell you which one your insurer will approve, and a clinician decides what to prescribe.
Zepbound vs Mounjaro at a glance
| Zepbound | Mounjaro | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Maker | Eli Lilly | Eli Lilly |
| FDA-approved uses | Long-term weight reduction in adults with obesity, or overweight plus at least one weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity | Blood-sugar control in adults and children 10+ with type 2 diabetes; lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk |
| Forms on the label | Single-dose pen, single-dose vial, multi-dose vial, KwikPen | Single-dose pen, single-dose vial, multi-dose vial, KwikPen |
| Strengths on the label | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| How often | Once a week, injected under the skin | Once a week, injected under the skin |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
| Lowest cash price at LillyDirect | $299 (2.5 mg KwikPen or vial) | "Starting at $499" (single-dose pen, every strength) |
| Medicare GLP-1 Bridge | KwikPen only, for eligible members | Not included |
Sources: Zepbound and Mounjaro prescribing information (both revised 08/2026), LillyDirect Zepbound, LillyDirect Mounjaro and Medicare.gov, read October 27, 2026. Which forms a pharmacy actually stocks can differ from what the label lists.
The right brand depends on your situation
Your diagnosis, your insurance and drug list, whether you're on Medicare, and how much you can pay each month all change the answer. Before choosing, use The RX Index's Find My GLP-1 Path tool. It's free, takes about 2 minutes, and needs no signup: you answer a few quick questions and get the GLP-1 paths and providers that fit your goals, budget, insurance and situation, with verified pricing and the right questions to ask.
Is Zepbound the same as Mounjaro?
Yes, the medicine is the same: Zepbound and Mounjaro both contain tirzepatide, made by Eli Lilly, and both labels list the same forms, strengths and boxed warning. What differs is the approved use, and with it insurance coverage, savings cards and cash price. Lilly sells one medicine under two names because each name carries its own FDA approval.
Three practical consequences follow from that:
- Don't expect a stronger version. The same strength contains the same medicine whichever name is on the box. Neither brand is the "weight-loss strength."
- They aren't taken together. Zepbound's label says using it with other tirzepatide products, or with any GLP-1 medicine, isn't recommended.
- The weight results come from Zepbound's label. Zepbound was tested for weight loss and sleep apnea; Mounjaro was tested for blood-sugar control and heart outcomes in type 2 diabetes. In the 72-week trial of adults without diabetes, average weight fell 15.0% to 20.9% depending on the dose, against 3.1% on placebo. In adults with type 2 diabetes it fell 12.8% to 14.7%, against 3.2%.
Those are trial averages, not a prediction for you. For why Mounjaro itself isn't approved for weight loss, see why Mounjaro isn't FDA-approved for weight loss. To compare tirzepatide with semaglutide (Wegovy, Ozempic), see tirzepatide vs semaglutide.
What Zepbound and Mounjaro cost
Paying cash at LillyDirect, Zepbound costs $299 to $449 a month with on-time refills and Mounjaro starts at $499 a month. With commercial insurance that covers your brand, each savings card can bring a fill down to as little as $25, within limits. The table shows what Lilly's own terms say you'd pay in each situation, checked October 27, 2026.
What you'd pay for each, by insurance situation
| Your situation | Zepbound | Mounjaro |
|---|---|---|
| Commercial plan covers it | As little as $25 for a 1-, 2- or 3-month fill of the single-dose pen with Lilly's savings card; card covers up to $100 of a 1-month fill and $1,300 a year | As little as $25 for a 1-, 2- or 3-month fill with Lilly's savings card; card covers up to $150 of a 1-month fill and $1,950 a year |
| Commercial plan doesn't cover it | As low as $499 per 1-month fill of the single-dose pen with the card; or the KwikPen at $299 to $449 (card limited to 11 fills a year) | As low as $499 per 1-month fill with the card |
| No insurance, paying cash | KwikPen or single-dose vial at LillyDirect: $299 to $449 with refills within 45 days | Single-dose pen at LillyDirect: "starting at $499/month" |
| Medicare Part D | Medicare GLP-1 Bridge: no more than $50 a month for the KwikPen if you qualify; otherwise depends on your plan and why it's prescribed | Through your Part D plan's diabetes coverage; Lilly's insurance savings card can't be used |
| Medicaid, TRICARE, VA or other government plan | Program rules decide; Lilly's insurance savings cards exclude you | Program rules decide; Lilly's savings card excludes you |
Sources: Lilly's Zepbound coverage and savings terms and Mounjaro savings terms, LillyDirect Zepbound, LillyDirect Mounjaro, and Medicare.gov.
Cash price per fill at LillyDirect, by strength
| Strength | Zepbound KwikPen or single-dose vial | Mounjaro single-dose pen (Lilly: "starting at") |
|---|---|---|
| 2.5 mg | $299 | $499 |
| 5 mg | $399 | $499 |
| 7.5 mg | $449 with a refill within 45 days; otherwise $499 | $499 |
| 10, 12.5 or 15 mg | $449 with a refill within 45 days; otherwise $699 | $499 |
A Zepbound fill covers 28 days: one KwikPen or four vials. Lilly lists Mounjaro as "starting at $499/month" without defining the month on that page. For Zepbound, pen needles (KwikPen) or needles and syringes (vials) are required, sold separately, and not priced on LillyDirect's page. The strength you take is your clinician's decision; this table only shows what each strength costs.
Read the fine print before you count on a number:
- The $25 isn't guaranteed. Each card has a monthly cap. Zepbound's card covers up to $100 of a 1-month fill, so a $200 copay would still leave you paying $100. Mounjaro's cap is $150.
- The $449 Zepbound price depends on timing. Miss the 45-day refill window on 7.5 mg or higher and the price is $499 or $699, which is more than Mounjaro's $499.
- The KwikPen self-pay card has 11 fills a year. At 28 days per fill, a full year is 13 fills. Lilly's terms don't say what the extra two cost, so ask LillyDirect before you budget.
- Every card ends December 31, 2026. Lilly's terms for both brands say "Card expires and savings end on 12/31/2026." Lilly hadn't posted 2027 terms on the pages we read.
- Approved use only. Both cards require a prescription for a use on the brand's FDA label. A Mounjaro prescription for weight loss alone doesn't meet that rule.
TrumpRx lists both and sends orders to LillyDirect at the same prices: Zepbound at $299 a month against a listed original price of $1,087, and the Mounjaro pen at $499 against $1,112.16 (TrumpRx Zepbound, TrumpRx Mounjaro). For deeper detail, see the Zepbound savings card guide, the Mounjaro savings card guide, cheapest Zepbound without insurance, Mounjaro cost without insurance and our TrumpRx Zepbound page. Lilly says HSA and FSA eligibility "may vary by plan"; whether your account pays is a separate question from coverage, covered in is Zepbound HSA/FSA eligible and is Mounjaro HSA/FSA eligible.
If you'd rather have a telehealth service handle it: Ro sells the Zepbound KwikPen for cash at the same $299 to $449, plus a membership. That's $39 for the first month (refunded if Ro finds you aren't eligible), then $149 a month on the monthly plan, or the equivalent of $74 a month if you prepay a year. The first month on the monthly plan comes to $338 ($39 + $299 at 2.5 mg) and a later month at $449 comes to $598 ($149 + $449), before pen needles. Ro doesn't list Mounjaro, so it isn't the route if you have type 2 diabetes and want Mounjaro. A prescription is never guaranteed.
See Ro's Zepbound KwikPen pricing (sponsored affiliate link, opens in a new tab)
Which one will insurance cover?
Coverage follows the label. Plans review Mounjaro as a diabetes drug, so they typically look for a type 2 diabetes diagnosis. Zepbound is covered only if your plan includes weight-management or sleep-apnea drugs. Either may need prior authorization, a permission request your prescriber files with the insurer before it will pay.
What that looks like in practice (an illustration, not a real case): someone with a BMI of 33, no diabetes, and an employer plan that excludes weight-loss drugs won't get Zepbound covered for weight, and Mounjaro isn't labeled for them. Their realistic paths are the Zepbound savings card's not-covered price ($499 for the single-dose pen) or LillyDirect cash ($299 to $449 for the KwikPen or vial). If the same person had moderate to severe sleep apnea, Zepbound's sleep-apnea approval gives the plan a second reason it may cover it.
Questions to put to your plan before your appointment:
- Is Zepbound, Mounjaro or both on your drug list, and for which diagnoses?
- Is prior authorization required, and what does it ask for (BMI, diagnosis codes, a sleep study for sleep apnea)?
- Is the Zepbound KwikPen covered, or only the single-dose pen? That changes which savings card applies.
- Does your plan use an alternate funding program? Lilly's cards don't work with those.
More detail by brand: does insurance cover Zepbound for weight loss, does insurance cover Mounjaro for weight loss, Zepbound for sleep apnea coverage, and how to appeal a Zepbound or Mounjaro denial.
If you have commercial insurance and want Zepbound, Ro offers a free insurance check for the Zepbound single-dose pen, and its team handles the prior-authorization paperwork. If it's approved, you pick the pen up at a local pharmacy. Ro's membership applies, and approval is up to your insurer. See also Zepbound providers that help with prior authorization.
Check your Zepbound coverage with Ro (sponsored affiliate link, opens in a new tab)
Medicare, Medicaid and other government plans
Medicare treats the two brands differently, and its own rules come first. The Medicare GLP-1 Bridge, which runs July 1, 2026 through December 31, 2027, covers Zepbound for weight management at a $50 monthly copay, but only the KwikPen, not single-dose vials or pens. It doesn't include Mounjaro.
To qualify, Medicare.gov says you need Part D coverage, must be 18 or older, and must meet a BMI rule: 35 or higher; 30 or higher with a qualifying heart, blood-pressure or kidney condition; or 27 or higher with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. You're not eligible for the Bridge if you have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease, or if your Part D plan already covers your GLP-1. Medicare.gov adds that in those cases your Part D plan might cover it. Prior authorization and a lifestyle-program certification are required. The Bridge sits outside the Part D benefit, so the $50 doesn't count toward your Part D out-of-pocket maximum, and Extra Help doesn't apply.
- Type 2 diabetes on Medicare: Mounjaro goes through your Part D plan's regular coverage. Lilly says Mounjaro is covered on many Part D plans for type 2 diabetes and, citing IQVIA data from October 2024 to September 2025, that about 8 in 10 Part D patients paid $0 to $50 for a 28-day supply.
- Sleep apnea with obesity on Medicare: not a Bridge case; ask your Part D plan whether it covers Zepbound for sleep apnea.
- Weight only on Medicare: the Bridge is the path, KwikPen only.
- Paying cash on Medicare: Lilly's Zepbound page still shows KwikPen and vial self-pay from $299 for Medicare members, but Lilly's KwikPen self-pay card terms say you won't seek reimbursement from any state or federal program, Medicare included, or count those costs toward a true out-of-pocket requirement. Lilly's insurance savings cards exclude anyone in a government program, including Medicare, Medicaid, TRICARE and VA.
Medicaid coverage differs by state. See does Medicare cover Zepbound, does Medicare cover Mounjaro for weight loss, does the Medicare GLP-1 Bridge cover Zepbound vials, does Medicaid cover Zepbound and does Medicaid cover Mounjaro. Sources: CMS Medicare GLP-1 Bridge, Medicare.gov, Mounjaro savings terms.
Compounded tirzepatide is a separate thing
Compounded tirzepatide is neither Zepbound nor Mounjaro. It isn't FDA-approved, and the FDA doesn't review compounded drugs for safety, effectiveness or quality. The FDA says that as of May 31, 2026 it had received more than 730 adverse event reports involving compounded tirzepatide. On April 1, 2026, the FDA said tirzepatide isn't on its drug shortage list or its 503B bulks list, which limits who can compound it. In February 2026 it said companies can't claim compounded products are generic versions of, or the same as, approved drugs.
If someone tells you their compounded product "is Mounjaro" or "is Zepbound," treat that as a red flag. For how the two paths differ, see compounded GLP-1 vs name brand and the 503B bulks list explained. Sources: FDA on concerns with unapproved GLP-1 drugs, its April 1, 2026 statement and its February 6, 2026 announcement.
Who usually ends up on which
| Your situation | Brand that matches the label | What decides cost |
|---|---|---|
| Obesity or overweight plus a weight-related condition, no diabetes | Zepbound | Whether your plan covers weight drugs; otherwise Zepbound card or LillyDirect cash |
| Obesity with moderate to severe sleep apnea | Zepbound | Your plan's sleep-apnea coverage and prior authorization |
| Type 2 diabetes (adults, or children 10+) | Mounjaro | Your plan's diabetes coverage and the Mounjaro card |
| Type 2 diabetes and obesity | Either label can apply; your clinician chooses | Which brand your plan covers |
| Medicare, weight only, meets the BMI rule | Zepbound KwikPen through the Bridge | $50 copay |
| Medicare with type 2 diabetes | Mounjaro | Your Part D plan |
| Paying cash, no diabetes | Zepbound | $299 to $449 at LillyDirect with on-time refills |
The type 2 diabetes and obesity row is based on Zepbound's label covering adults with overweight or obesity whether or not they have diabetes, and its trials included adults with type 2 diabetes.
Already on one and thinking of moving to the other? That's a prescription change for your clinician, and our guides cover it: switching from Mounjaro to Zepbound and switching from Zepbound to Mounjaro.
Find the tirzepatide path that fits you
What we actually verified
- Read the current Zepbound and Mounjaro prescribing information (both revised 08/2026) for indications, forms, strengths, the boxed warning and Zepbound's trial results.
- Opened LillyDirect's Zepbound and Mounjaro pages and recorded every price shown, by strength.
- Read the full savings card terms on Lilly's Zepbound and Mounjaro sites, including caps, fill limits and the December 31, 2026 end date.
- Opened TrumpRx's Zepbound and Mounjaro listings.
- Read the CMS and Medicare.gov pages for the Medicare GLP-1 Bridge.
- Opened Ro's pricing and Zepbound pages.
- Read the FDA's compounding pages dated February 6, 2026 and April 1, 2026 and its page on concerns with unapproved GLP-1 drugs.
What we did not do: place an order, run any checkout, confirm pen-needle prices, confirm what Lilly charges for KwikPen self-pay fills beyond 11 a year, confirm how Ro's annual prepay interacts with its $39 first month, or check what any specific insurance or Medicaid plan covers. Prices, card terms and Medicare rules can change; check the source before you pay.
Frequently asked questions
Does Zepbound work as well as Mounjaro?
They contain the same medicine, tirzepatide, in the same strengths, so neither brand is stronger. What differs is what each was tested and approved for: Zepbound for weight loss and sleep apnea, Mounjaro for blood-sugar control and heart outcomes in type 2 diabetes. Your result depends on you and your dose, not the name on the box.
Which is more expensive, Mounjaro or Zepbound?
Paying cash at LillyDirect, Zepbound is usually cheaper: $299 to $449 a fill for the KwikPen or vial with refills within 45 days, against Mounjaro's starting price of $499 a month. If you miss the refill window on 10 mg or higher, Zepbound rises to $699. With covered commercial insurance, both savings cards start as low as $25, within monthly caps.
Is Zepbound the same as Mounjaro?
The medicine is the same: both are tirzepatide, made by Eli Lilly, with the same forms, strengths and boxed warning. The FDA-approved uses differ. Zepbound is for weight management and sleep apnea with obesity, and Mounjaro is for type 2 diabetes, which is why coverage and prices differ.
Can my doctor prescribe Mounjaro for weight loss?
A clinician can legally prescribe a drug off-label, but weight loss isn't on Mounjaro's label, and that is your clinician's decision. Plans often won't cover Mounjaro without a type 2 diabetes diagnosis, and Lilly's Mounjaro savings card requires an approved use. For weight management, Zepbound is the tirzepatide brand labeled for it.
Can I use the Mounjaro savings card if I'm taking it for weight loss?
Lilly's terms say the card is for a prescription "for an approved use consistent with FDA-approved product labeling," and weight loss alone isn't on Mounjaro's label. The Zepbound savings card is the one built for weight management and sleep apnea prescriptions. Both cards end December 31, 2026, under the current terms.
Does Medicare cover Zepbound or Mounjaro?
Lilly says Mounjaro is covered on many Part D plans for type 2 diabetes. Zepbound for weight management is covered through the Medicare GLP-1 Bridge at $50 a month, KwikPen only, if you meet the BMI and Part D rules and don't have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease. For sleep apnea, ask your Part D plan.
Can you take Zepbound and Mounjaro together?
No. Zepbound's label says using it with other tirzepatide products, which includes Mounjaro, or with any GLP-1 medicine isn't recommended. They're the same medicine under two names. Any change should go through your clinician.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded tirzepatide isn't FDA-approved, and the FDA doesn't review compounded drugs for safety, effectiveness or quality. The FDA has said companies can't claim compounded products are the same as approved drugs.
Sources
- Prescribing information: Zepbound, Mounjaro (both revised 08/2026; checked October 27, 2026)
- Lilly prices and terms: LillyDirect Zepbound, LillyDirect Mounjaro, Zepbound coverage and savings, Mounjaro savings (checked October 27, 2026)
- TrumpRx: homepage, Zepbound, Mounjaro (checked October 27, 2026)
- Medicare: Medicare.gov weight-loss drugs, CMS Medicare GLP-1 Bridge (checked October 27, 2026)
- Ro: pricing, Zepbound (checked October 27, 2026)
- FDA: concerns with unapproved GLP-1 drugs, April 1, 2026 compounding statement, February 6, 2026 announcement (checked October 27, 2026)
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.